Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CYP3A4 Inhibitor and Inducer on PK of Darolutamide (ODM-201)
NCT03048110Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to 72 Hours of Darolutamide in Plasma, Maximum Observed Concentration of Darolutamide in Plasma and 6 more. Started Feb 2017; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03048110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048110.